Ask three suppliers to quote the same nominal product and the numbers can differ by an order of magnitude. That spread is not evidence that someone is overcharging. It usually means the three quotes describe materially different things, and the differences are invisible unless you know which variables move the number. Understanding the drivers is more useful than collecting prices, because the drivers are what you actually control.
Grade is the largest multiplier, and it is not a label
Moving material from research use to cGMP changes almost everything behind it. The input materials change to GMP-grade equivalents, including more extensively tested selection reagents. The contracting changes, because a clinical master services agreement is required. Testing expands, including sterility. Documentation and signature requirements extend. Review adds Medical Director and Lab Director sign-off. And release moves from a technical decision to a Quality Assurance decision.
Each of those is real work performed by real people against a documented system, and together they explain most of the gap between a research quote and a clinical one. When a supplier’s GMP price sits close to their research price, that is a question rather than a bargain.
Format, volume and the per-cell arithmetic
Whole, half and quarter units are not simply the same product divided. Each format carries its own processing, its own documentation and its own handling, so the per-cell economics generally improve with size while the absolute figure rises. A screening study that buys whole units because whole units were quoted is paying for cells it will never thaw.
The reverse error is more expensive. Buying quarter units for a program that will need whole units later means the comparability question arrives at the same time as the scale-up question.
Fresh and cryopreserved carry different costs, not different amounts
| Fresh | Cryopreserved | |
|---|---|---|
| What you are paying for | Scheduling, courier priority, coordination against a collection date | Cryopreservation process, controlled-rate freezing, long-term vapor-phase storage |
| Hidden cost | A failed run cannot be repeated; the collection is gone | Storage accrues for as long as the lot is held |
| Where it saves you | No freeze-thaw damage, no rest period | Repeatability, multi-site studies, second attempts from the same lot |
The comparison people skip is the cost of a failed experiment. A fresh collection that fails takes the donor with it. A frozen lot that fails leaves a second vial and the variable you cared about held constant, which is frequently worth more than the difference in unit price.
How specific your donor criteria are
A unit from any eligible healthy donor and a unit from a donor with a defined HLA genotype, a particular cytomegalovirus status and an age band are different sourcing problems. The first is inventory. The second is a scheduled collection against criteria, which means donor identification, availability and coordination.
Specificity is worth paying for when it removes variance you would otherwise have to explain. It is worth avoiding when it is habit rather than requirement. Programs routinely specify criteria they inherited from a previous protocol and never revisit, and every one of those constraints narrows the pool.
How much characterization ships with it
Two units with identical cell counts are not equivalent products if one arrives with a characterized donor and the other arrives with a lot number. Characterization depth is a genuine cost driver because the assays are genuine work.
The distinction worth understanding is between characterization run at program level and characterization run per order. Program-level characterization, where HLA and KIR genotype are already known across the donor pool, costs less per unit and, more importantly, makes those attributes available as selection criteria rather than as after-the-fact documentation.
Whether you need the same donor again
Continuity is priced differently from a one-off purchase because it commits something on the supplier’s side. A program that needs four more units from a specific donor in eighteen months is asking for a scheduled recall, not a stock check, and that has to be scoped rather than assumed.
The alternative is cheaper per unit and more expensive per program. Losing donor continuity midway through development means the comparability work is repeated, and that cost lands on the timeline rather than on the invoice, which is where it hurts more.
The mistake that actually costs money
It is rarely the unit price. It is qualifying a supplier at research grade, building a process around that material, and then discovering that the clinical-grade version comes from a different donor pool under a different quality system. The comparability work goes back on the schedule, the filing waits, and the saving that justified the original decision disappears several times over.
Which makes the single most valuable question at quote stage a structural one rather than a commercial one: does the GMP material come from the same donors, under the same quality system, as the research material I am about to qualify?
Scoping a quote that means something
Bring the grade, the format and volume, whether fresh or cryopreserved, your genuine donor criteria as distinct from inherited ones, the characterization you need attached, and whether the program will need continuity. A quote against those six is comparable between suppliers. A quote against “PBMCs” is not.
OrganaBio documents research and cGMP formats across the leukopak portfolio and the isolated populations derived from the same donors, including cryopreserved PBMCs, pan T cells and NK cells, with donor characterization applied at program level. Scope specific requirements with the scientific team.
Frequently asked questions
Why do quotes for the same cell product vary so much between suppliers?
Because the quotes usually describe materially different things. Grade, format and volume, fresh versus cryopreserved, how specific the donor criteria are, how much characterization is attached, and whether the program needs donor continuity all move the figure independently.
Why is GMP material more expensive than research grade?
The inputs change to GMP-grade equivalents, a clinical master services agreement is required, testing expands to include sterility, documentation and signature requirements extend, review adds Medical Director and Lab Director sign-off, and release moves from a technical decision to a Quality Assurance decision. Each is real work against a documented system.
Does GMP grade mean the material can be given to a patient?
No. GMP starting material is manufactured for further manufacturing. The grade provides a quality system your own filing can reference; it does not by itself make material suitable for direct human administration.
Is fresh or cryopreserved cheaper?
They carry different costs rather than a simple ranking. Fresh carries scheduling and courier priority against a collection date. Cryopreserved carries the freezing process and ongoing storage. The comparison most buyers omit is the cost of a failed run, which a frozen lot can absorb and a fresh collection cannot.
Do tighter donor selection criteria cost more?
Yes, because a defined genotype with a specific serostatus is a scheduled collection against criteria rather than a stock check. It is worth paying for when it removes variance you would otherwise have to explain, and worth revisiting when the criteria were inherited from an older protocol rather than genuinely required.
What is the most expensive mistake in sourcing starting material?
Qualifying a supplier at research grade, building a process on that material, then finding the clinical-grade version comes from a different donor pool under a different quality system. The comparability work returns to the timeline, which costs far more than any difference in unit price.
What information should I give a supplier to get a comparable quote?
Grade, format and volume, fresh or cryopreserved, your genuine donor criteria, the characterization you need attached to the unit, and whether the program will require repeat collection from the same donor. A quote scoped against those six can be compared between suppliers.
Working through this on a live program?
The scientific team works through sourcing and specification questions with cell therapy and research groups directly, including donor characterization, format selection and documentation scope.
